The US Food and Drug Administration (FDA) has approved an amphetamine extended-release orally disintegrating tablet (Adzenys XR-ODT) for the treatment of attention ...
Please provide your email address to receive an email when new articles are posted on . The FDA recently approved Adzenys XR-ODT for the treatment of attention ...
Please provide your email address to receive an email when new articles are posted on . APT-1011, a novel fluticasone orally disintegrating tablet, effectively induced histologic response, improved ...
Objective: To compare the flavour and taste preferences of two acid-inhibitory therapies in children. Subjects and Setting: 104 (52 male and 52 female) healthy children aged 6-11 years participated in ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today ...
A recently filed patent (Publication Number: US20230263735A1) describes a film-coated tablet with specific compositions and properties. The tablet consists of a core tablet coated with two film layers ...
Korea's 37th homegrown new drug for gastroesophageal reflux disease, Ja Q Bo (ingredient name: zaztaprozan), has been released in an orally disintegrating tablet (ODT) formulation that can be taken ...
Omeprazole ODT utilizes MelTech technology that allows the tablet to dissolve in the mouth without water. Perrigo announced the launch of store brand Omeprazole Delayed Release Orally Disintegrating ...
DALLAS and FORT WORTH, Texas, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc.(Nasdaq:NEOS), a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results